NCT01524289View on ClinicalTrials.gov

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

PHASE3CompletedINTERVENTIONAL

Enrollment

306

Participants

Timeline

Start Date

February 3, 2012

Primary Completion Date

February 12, 2014

Study Completion Date

November 13, 2018

Conditions

Hyperlipoproteinemia Type IIHypercholesterolemia, Familial

Interventions

DRUG

Anacetrapib

One oral tablet, orally once daily for 52 weeks

DRUG

Placebo

One oral tablet once daily for 52 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01524289 - Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) | Biotech Hunter | Biotech Hunter